**ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR**

Yuan Li, Yunjian Pan, Rui Wang, Yihua Sun, Haiichuan Hu, Xuxia Shen, Yongming Lu, Lei Shen, Xiongzeng Zhu, Haiquan Chen

1 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 2 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, 3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

**Abstract**

Approximately 3–7% of non-small cell lung cancers harbor an anaplastic lymphoma kinase (ALK) gene fusion, constituting a new molecular subtype of lung cancer that responds to crizotinib, an ALK inhibitor. Although previous studies have evaluated ALK-rearranged lung cancers, the comprehensive analysis of lung cancer in Chinese has not well assessed. Herein, we identified 44 cases of ALK-rearranged samples by fluorescent in-situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcription polymerase chain reaction (RT-PCR) in a large number of surgically resected lung cancers. All 44 ALK-rearranged lung cancers were adenocarcinomas, with 2 cases having additional focal squamous components. The goal was to analyze the clinicopathological features of ALK-rearranged lung adenocarcinomas. Our data showed that a cribriform structure, prominent extracellular mucus and any type of mucous cell pattern may be either sensitive or specific to predict an ALK rearrangement. We used FISH as the standard detection method. We compared the ALK rearrangement accuracy of FISH, RT-PCR and IHC. RT-PCR could define both the ALK fusion partner and the fusion variant, but seemed unable to detect all translocations involving the ALK gene. It is noteworthy that IHC using the D5F3 antibody (Cell Signaling Technology) showed higher sensitivity and specificity than the ALK1 antibody (Dako). Therefore, we conclude that IHC remains a cost-effective and efficient technique for diagnosing ALK rearrangements and that D5F3 can be the optimal screening antibody in clinical practice.

**Introduction**

Lung cancer remains the leading cause of cancer-related death in the world. The clinical importance of the molecular phenotype of lung cancer lies mainly in its therapeutic implications since different subtypes may respond to different target treatments. A fusion gene that joins the echinoderm microtubule-associated protein-like 4 (EML4) gene with the anaplastic lymphoma kinase (ALK) gene was found in a subset of non-small-cell lung carcinomas (NSCLCs) in 2007 [1]. This fusion occurred due to chromosomal inversion or translocation on chromosome 2p, resulting in formation of the EML4-ALK fusion gene. Despite the relatively low frequency of the EML4-ALK fusion, ALK-rearranged lung cancer is a unique molecular subgroup with a high sensitivity to ALK inhibitors, and is mutually exclusive from other well-known oncogenic mutations involving EGFR or KRAS [2–5]. To better understand ALK-rearranged lung cancers, it is important to characterize their clinicopathologic features. The results of detailed clinicopathologic analyses have varied. In our study, 572 lung adenocarcinomas were divided into ALK-rearranged, common driver mutation, and pan-negative groups according to mutational status. We compared clinicopathological features of the ALK-positive group with common driver mutation, and with pan-negative group, seeking to assess whether there were distinctive clinicopathological features associated with ALK rearrangement cohort. ALK-rearranged lung cancer can be identified by IHC, FISH, or RT-PCR with each method having advantages and disadvantages for screening. Current clinical trials of crizotinib use FISH as the diagnostic test [6]. However, FISH requires specialized technical resources and expertise, and the signals rapidly fade over time. Furthermore, the cost of FISH assay limits its application for screening in clinical practice. RT-PCR coupling direct sequencing has been used to identify known fusion variants, but may miss unknown variants. IHC is relatively inexpensive, faster, and performed routinely on formalin-fixed paraffin-embedded (FFPE) tissues. However, the results of ALK IHC testing in lung cancer remains to be unsatisfied because of relatively low sensitivity or specificity, and absence of an ideal antibody. Now, the highly sensitive ALK monoclonal antibody, D5F3 can recognize epitopes...
within the ALK protein of all known fusions. IHC is readily available in routine pathology practice and the test costs only one-twentieth of FISH test in China. Therefore, this IHC analysis holds the promise of being cost-effective and a rapid screening method [7]. However, the accuracy and sensitivity of the D5F3 antibody have not been thoroughly tested. We compared the concordance among IHC, FISH and RT-PCR to determine the optimal screening method. FISH is the most accurate method and RT-PCR can define most ALK fusion variants, but may not detect all ALK translocations. We found that IHC with D5F3 monoclonal antibody showed both high sensitivity and specificity (91% and 98%, respectively) and thus might be routinely applicable in clinical practice.

Materials and Methods

Case Selection

A total of 572 frozen lung adenocarcinoma tissue samples and their corresponding paraffin-embedded tumor tissues were obtained at the Fudan University Shanghai Cancer Centre from Oct 2007 through Jun 2011, with written informed consents from all patients. All research involving human participants in this study was approved by the Ethics Committee of Shanghai Cancer hospital (shanghai cancer center), Fudan University, China. We previously demonstrated that 90% of lung adenocarcinomas from never-smokers harbored mutually exclusive oncogenic mutations in just four genes (EGFR, KRAS, HER2 and ALK) [8]. In current study, we had included 527 lung adenocarcinomas irrespective of smoking status besides the 45 tumors (41 EGFR, 3 EML4-ALK fusions and 1 KRAS) previously published [8]. There were 411 of 572 samples which harbored known mutations, including 361 EGFR, 40 KRAS and 10 BRAF tumors, while 161 of 572 samples did not harbor any of the above mutations. For detection of EML4-ALK fusions, primers were designed to amplify all known fusion variants, using cDNA, as described previously [9]. According to mutational status, 572 lung adenocarcinomas were divided into three groups. There were 44 cases identified as ALK rearrangement by FISH and grouped as ALK-positive. There were 411 cases which harbored well-known oncogenic mutations (361 EGFR, 40 KRAS and 10 BRAF) identified by RT-PCR and grouped as common drive mutations. There were 117 cases which were defined as those presenting overlapping of red and green signals. The distance between two separated signals was estimated using twice the size of the biggest signal size. Another definition was an isolated red signal pattern with one fusion signal and one red signal without a corresponding green signal. Positive cases were defined as more than 15% break-apart signals or isolated red signal signals in 50 tumor cells. FISH-negative cases were defined as those presenting overlapping of red and green signals (yellowish) in tumor cells, indicating that ALK was not rearranged.

Fluorescence in situ hybridization

ALK-rearranged lung cancer is a molecular subgroup and mutually exclusive from other mutations such as EGFR, KRAS and BRAF. The 161 cases which did not harbor any of the above mutations were subjected to FISH. FISH was performed on formalin-fixed paraffin-embedded (FFPE) specimens using a commercially available break-apart probe specific to the ALK gene (Vysis LSI ALK Dual Color, break-apart rearrangement probe; Abbott Molecular, Abbott Park, IL) according to manufacturer’s instructions. The probe hybridized to band 2p23, on either side of the ALK gene breakpoint. The 5’ ALK signal was labeled with Spectrum Green (green), and the 3’ ALK signal was labeled with Spectrum Orange (orange). 4, 6-diamidino-2-phenylindole (DAPI) II was applied for nuclei counterstaining. Signals for each probe were evaluated under microscope equipped with triple-pass filter (DAPI/Green/Orange; Abbott Molecular) and oil immersion objective lens. FISH-positive cases were defined as two positive ALK rearrangement patterns. One was the break-apart pattern with one fusion signal and two separated orange and green signals. The distance between two separated signals was estimated using twice the size of the biggest signal size. Another definition was an isolated red signal pattern with one fusion signal and one red signal without a corresponding green signal. Positive cases were defined as more than 15% break-apart signals or isolated red signal signals in 50 tumor cells. FISH-negative cases were defined as those presenting overlapping of red and green signals (yellowish) in tumor cells, indicating that ALK was not rearranged.

Immunohistochemistry

There were 161 cases which did not harbor any of above mutations. These were subjected to D5F3, ALK1, p63 and TTF-1 IHC. IHC was performed on 4 µm thick FFPE sections. Slides were deparaffinized and pretreated with 1 mmol/L EDTA and heat-mediated antigen retrieval solution in a microwave oven. Further steps were done at room temperature in a hydrated chamber. Slides were incubated in 20% normal goat serum. ALK (D5F3) XP Rabbit monoclonal antibody (Cell Signaling Technology, Danvers,MA), Mouse monoclonal antihuman ALK1 (Dako) at 1:10 dilution in Dako diluent, p63 (1:400, 4A4, DAKO), and TTF-1 (1:100, 8G7G3/1, DAKO) were applied. The slides were then washed in Tris-HCl and detected with horseradish peroxidase-conjugated anti-rabbit EnVision+ kit (Dako). All slides were counterstained with hematoxylin.

Cytoplasmic staining was regarded as positive for D5F3 and ALK1. This recognizes epitopes within the ALK protein that are preserved in all known ALK fusions. IHC staining was scored as follows: 0 (no staining); 1 (faint, cytoplasmic staining); 2 (moderate, smooth cytoplasmic staining); 3 (intense, granular cytoplasmic
staining) in more than 10% of tumor cells. Scoring was performed by two pathologists. Nuclear staining of tumor cells was considered positive for TTF-1 and p63.

Statistical analysis

The associations of lung adenocarcinomas with ALK-positive and common driver mutation or pan-negative group with clinical characteristics were assessed using Chi-square (for categorical data) and Wilcoxon rank-sum (for continuous data) tests. p values were based on a two-sided hypothesis. p values less than 0.05 were considered significant.

Results

Clinical features of ALK-rearranged lung cancer

The 572 surgically resected stage I–IV lung adenocarcinomas patients were all from China, their ages ranging from 22 to 84 years, with an average of 59 years. Patients were composed of 215 men and 357 women. Tumor diameters ranged from 0.5 to 11 cm. Pathologic stages were I in 285 and II–IV in 287 patients. According to mutational status, the 572 patients were divided into three groups, named ALK-positive group (44 cases), common driver mutation group (411 cases) and pan-negative group (117 cases). In all ALK-positive cases, no concurrent activating mutations in EGER, KRAS and BRAF were detected. We compared clinicopathological features of the ALK-positive group with the common driver mutation and pan-negative groups. Of the cases with clinical data available, ALK-positive lung cancers were associated with younger age compared with the common driver mutation group (p = 0.023, Table 1), but age in ALK-positive group was not significantly difference from the pan-negative group (p = 0.83, Table 1). The ALK-positive group was associated with no-smoking history compared with pan-negative patient (p<0.001, Table 1), while the ALK-positive group showed no significance difference compared with the common driver mutation group (p = 0.828, Table 1). Although ALK-rearranged patients showed a tendency for association with positive lymph nodes status and higher stage in previous reports [12,13], our ALK-positive group had no significance difference from the other 2 groups. Clinical characteristics of the ALK-positive group, common driver mutation group, and pan-negative group are summarized in Table 1.

Pathological findings of ALK-rearranged lung cancers

Table 1 summarizes the pathological features of all 44 cases. All 44 were adenocarcinomas and 2 had additional focal squamous components (account for 10% of tumor volume). According to pattern-based grading system, there were no differences in tumor grade between ALK-positive, common driver mutation or pan-negative groups (p = 0.59 and p = 0.344, respectively). According to the predominance subtypes based on the IASLC/ATS/ERS classification, our ALK-positive group had various predominant subtypes: acinar 15 cases (34.09%), solid 19 cases (43.18%), lepidic 1 case (2.27%), papillary 6 cases (13.64%), micropapillary 1 case (2.27%, Figure 1A), mucinous 2 cases (4.55%). The ALK-positive tumors were significantly associated with solid- and acinar-predominant patterns compared with common driver mutant adenocarcinomas (p<0.0001 and p = 0.013, respectively), while not significantly associated with other predominant histologic patterns. In addition, ALK-positive tumors were not significantly associated with any predominant histologic patterns compared with pan-negative adenocarcinomas.

ALK-positive tumors were also associated with distinct morphological features. Of the 44 tumors, 52.27% (23/44) showed a cribriform pattern (Figure 1B), either focal or diffuse. In contrast, only 20 of 411 common driver mutant (p<0.001) and 34 of 117 pan-negative tumors had a cribriform pattern (p = 0.006). There were 29.55% (13/44) of ALK-positive but only 2% (8/411) of common driver mutant tumors (p<0.001) which had at least some degree of signet ring cells (Figure 1C). Signet-ring cells were associated with a solid predominant pattern in 11 ALK-positive tumors, an acinar pattern in 1, and both acinar and solid patterns in one. The ratio of signet-ring cells to total tumor cells varied, with a range of 5 to 80 percent. Interestingly, ALK-positive tumors were not significantly associated with signet-ring cells pattern compared with pan-negative tumors, demonstrating that the signet-ring pattern would be more rare in ALK-positive lung cancer. Also found were prominent extracellular mucus and any type of mucous cells were all significantly more common in ALK-positive tumors (P<0.0001) compared with the other 2 group (p<0.001). In 22 cases (50%) there was prominent extracellular mucus, with mucus expanding into alveolar spaces at the tumor periphery (Figure 1D). Any type of mucous cells was found in 26 cases (59.09%) and had various pattern, but they were found most often in a solid or acinar pattern. Mucous cells were most often signet-ring and columnar goblet types (Figure 1E). In 2 mucinous cases, goblet cells proliferated in acinar and lepidic patterns. In 11 (25%) cases there was at least a focal population of hepatoid tumor cells with abundant eosinophilic cytoplasm, round nuclei, and prominent nucleoli in a predominantly solid pattern (Figure 1F). In addition, no single histologic pattern was completely sensitive or specific to predict ALK rearrangement, and even cases with signet-ring cell or cribriform patterns could be present in the other 2 groups. In all ALK-positive cases, the tumor cell nuclei were relatively monomorphic (Figure 1F), except for two cases showing focal areas of pleomorphism. Of the 44, 40 were TTF-1 positive, while in 6, the foci of adenocarcinoma co-expressed TTF-1 and p63.

EML4-ALK fusion variant detection by multiplex RT-PCR and sequencing in frozen material

We investigated the presence of the EML4-ALK fusion variant in 161 cases which did not harbor EGFR, KRAS and BRAF by RT-PCR. We identified 38 cases of EML4-ALK fusion variant by RT-PCR. EML4-ALK variant 1 was detected in 19 samples. Five cases were variant 2, 7 cases were variant 3a/3b and 1 was V3b, E17; A20, E17 ins 65; A20, E17b ins 39; A20 E10a/b, E13; A20, E6a/b ins 18; A20 and E6a; A19 each (Table 2, Figure 2A). Two cases were positive as identified by FISH. Typically, two distinct splits in red and green signals were noted 38 cases (Table 2, Figure 2A). Six of the FISH-positive cases were characterized by loss of one green signal (Figure 2B). Three of these 6 cases were two variant 1 cases, one variant 3b case and three negative cases. Six RT-PCR-negative cases were positive by FISH. Two cases of the coexistence of both adenocarcinoma and focal squamous cell carcinoma demonstrated FISH-positive signal to be present only in the adenocarcinoma component.

ALK rearrangements detection by FISH

There were 161 cases were subjected to ALK FISH. ALK rearrangement is usually defined by split green and orange signals located at least twice the times of largest signal size. There were 44 cases positive as identified by FISH. Typically, two distinct splits in red and green signals were noted 38 cases (Table 2, Figure 2A). Six of the FISH-positive cases were characterized by loss of one green signal (Figure 2B). Three of these 6 cases were two variant 1 cases, one variant 3b case and three negative cases. Six RT-PCR-negative cases were positive by FISH. Two cases of the coexistence of both adenocarcinoma and focal squamous cell carcinoma demonstrated FISH-positive signal to be present only in the adenocarcinoma component.

ALK rearrangements detection by IHC using ALK1 and DSF3 antibody

ALK IHC testing in lung cancer remains challenging because of the relatively low expression of ALK protein, with many results
showing this to be the case using ALK1 antibody. To determine whether IHC using the D5F3 antibody might be better, we evaluated both in 161 cases. ALK1 antibody expression was detected in 32, resulting in IHC scores of 1 (n = 14), 2 (n = 14), and 3 (n = 4), whereas 28 patients were FISH-positive (Table 2). We observed that all IHC 0 cases were FISH-negative, all IHC 3+ and 2+ cases were FISH-positive, 4 IHC 1+ cases were FISH-negative, and 10 IHC 1+ cases were FISH-positive. Among the 32 ALK1

Table 1. To compare the clinicopathologic characteristics of ALK-positive group respectively with common driver mutation group and pan-negative group.

| Variable                        | ALK+ (n = 44) | Common Mutation (n = 411) | Pan-negative (n = 117) |
|---------------------------------|---------------|--------------------------|-----------------------|
|                                 | No. Samples   | No. Samples              | No. Samples           |
| Age                             |               |                          |                       |
| Average≤59                      | 30            | 206                      | 62                    |
| >59                             | 14            | 205                      | 55                    |
| Mean(Years)                     | 56            | 60                       | 59                    |
| Median(Years)                   | 55            | 60                       | 59                    |
| Range(Years)                    | 22–82         | 27–84                    | 36–82                 |
| Sex                             |               |                          |                       |
| Male                            | 19            | 128                      | 68                    |
| Female                          | 25            | 283                      | 49                    |
| Smoking History(%)              |               |                          |                       |
| Never smoker                    | 31            | 283                      | 46                    |
| smoker                          | 13            | 128                      | 71                    |
| Tumor Size                      |               |                          |                       |
| <3 cm                           | 23            | 240                      | 46                    |
| ≥3 cm                           | 21            | 171                      | 71                    |
| Dominant histological subtype   |               |                          |                       |
| Lepidic predominant             | 1             | 48                       | 6                     |
| Acinar predominant              | 15            | 221                      | 45                    |
| Papillary predominant           | 6             | 74                       | 15                    |
| Solid predominant               | 19            | 53                       | 49                    |
| Micropapillary predominant      | 1             | 4                        | 0                     |
| mucinous adenocarcinoma         | 2             | 11                       | 2                     |
| Other histological pattern      |               |                          |                       |
| Cribriform pattern              | 23            | 20                       | 34                    |
| Signet-ring cell                | 13            | 8                        | 24                    |
| Hepatoid appearance             | 11            | 30                       | 18                    |
| Extracellular mucus             | 22            | 52                       | 25                    |
| Any type of mucous cells        | 26            | 63                       | 30                    |
| Grade                           |               |                          |                       |
| Grade I                         | 1             | 48                       | 6                     |
| Grade II                        | 14            | 294                      | 58                    |
| Grade III                       | 29            | 69                       | 53                    |
| Pleural Invasion                |               |                          |                       |
| Negative                        | 24            | 268                      | 79                    |
| Positive                        | 20            | 143                      | 38                    |
| Lymph Node Status               |               |                          |                       |
| Negative                        | 20            | 245                      | 50                    |
| Positive                        | 24            | 166                      | 67                    |
| Stage                           |               |                          |                       |
| I                               | 21            | 221                      | 43                    |
| II–IV                           | 23            | 190                      | 74                    |

*marks parameters showing statistical significance by univariate analysis.

doi:10.1371/journal.pone.0069016.t001
IHC-positive cases, only 4 IHC 3+ staining intensity, observed in 20% to 100% of positive cells (mean score of 60%). IHC1+ and 2+ cases were only observed in 10% to 50% of positive cells (mean score of 30%) (Figures 3B, 3D, 3F).

In our study, the D5F3 IHC test showed very high sensitivity and specificity for detecting ALK expression. D5F3 immunopositivity was identified in 41 cases (Figures 3A, 3C, 3E). Positive immunostaining was found only in the adenocarcinoma component of the 2 adenosquamous carcinomas. Among 41 D5F3-positive cases, 34 were 3+ exhibiting strong cytoplasmic staining intensity, observed in 60% to 100% of positive cells (mean score of 80%). Of the remaining 7 cases, 2 cases exhibited cytoplasmic and nuclear positive staining. There were 4 IHC-positive that were 2+, showing moderate cytoplasmic staining, and 3 IHC-positive cases were 1+, showing faint cytoplasmic staining. No background was observed in stromal cells or within normal lung. Compared the immunoreactivity of ALK1 antibody, D5F3 showed more intense staining of tumor cells. The relative amount of staining area with D5F3 was also much higher. Therefore, intensity scores of D5F3 antibody staining were higher than ALK1 antibody (Table 2).

Interestingly, D5F3 IHC results in 1 case illustrate that heterogeneous staining can occur. One tissue block showed no staining despite repeated IHC testing, while another block showed positive staining. FISH analysis confirmed the presence of the genetic abnormality. We considered the possibility that the differing results was due to heterogeneity.

Comparison between IHC and RT-PCR
There were 26 of 38 cases that were RT-PCR-positive were ALK1 IHC-positive, with the other 12 cases being IHC negative. Sensitivity of ALK1 IHC for the detection of ALK rearrangement was thus 68.4% (26 of 38) when compared with RT-PCR. However, 36 of 38 RT-PCR-positive cases were D5F3-positive (Table 3). Thus, sensitivity of D5F3 was 94.7% (36 of 38) when compared with RT-PCR (Table 3). D5F3-positive cases included variant 1, 2, 3a/3b, 3b, E17; A20, E17 ins 65; A20, E17b ins 39; A20, E10a/b, E13; A20, E6a/b ins 18; A20 and E6a:A19. Two D5F3-negative cases of the 38 RT-PCR-positive cases were a variant 3a/b and a E17b ins 39; A20 case (Table 2). Five of 123 RT-PCR negative cases were D5F3-positive.

Comparison between IHC and FISH
There were 28 of 44 FISH-positive cases that were ALK1 IHC-positive, and 4 ALK1 IHC-positive cases that were FISH-negative. The overall sensitivity and specificity of the ALK1 IHC in comparison with FISH were 64% and 91%, respectively. In contrast, 40 of 44 FISH-positive cases were D5F3-positive. Four of 44 FISH-positive cases were D5F3-negative. One FISH negative case was D5F3-positive. Overall sensitivity and specificity of D5F3 in comparison with FISH were 91% and 90% (Table 4).

Discussion
Although ALK-rearranged lung cancers make up only 5% to 7% of all NSCLC cases, they have demonstrated an impressive responsiveness to the ALK tyrosine kinase inhibitor, crizotinib, and represent a therapeutically important subcategory. Previous studies have evaluated ALK rearrangement lung cancer, but the comprehensive analysis of ALK-rearranged lung cancers in Chinese has not well assessed. We identified 44 cases of ALK-rearranged cases in 572 lung cancers. In our series, these tumors lacked mutation of EGFR, KRAS or BRAF, in agreement with the prior observations [14]. In previous reports, results of detailed clinicopathologic analyses of ALK-rearranged lung cancers have varied. A thorough study of clinicopathologic features of such patients compared with the common mutations EGFR and KRAS or rare unknown mutations is an emerging issue with clinical interest. We sought to compare the clinicopathologic features of ALK-rearranged lung cancer with the common driver mutations and pan-negative tumors.

Our main clinic findings of our study were as follows: (1) ALK-rearranged lung cancers were more frequent in younger patients compared with the common drive mutation group ($p=0.023$), in agreement with previous studies [4,15], while there was no significance difference compared with patients in pan-negative group ($p=0.83$). (2) ALK-rearranged patients associated with no smoking history compared with the pan-negative group ($p=0.001$), while smoking history of ALK-rearranged patients was not different from the common drive mutation group ($p=0.828$). (3) There were no differences in sex, tumor size, lymph node status, tumor grade or stage between ALK-positive, common driver mutation or pan-negative groups. This discrepancy may be due to the small number of cases examined in other study, or different experiment grouping design, or differences in the ethnicity. Therefore, the clinical characteristics alone are not sufficient to selecting individual cases for further testing for ALK rearrangement.

In our study, all 44 ALK-rearranged lung cancers were adenocarcinomas, with 2 cases having additional focal squamous components. Interestingly, in neither case was the ALK rearrangement present in the squamous cell component, confirmed by both FISH and IHC. This is in contrast with one report where ALK rearrangement coexisted in both components [15]. Although most ALK-rearranged lung cancers are adenocarcinomas, other histological types should not exclude its presence. In our study, ALK-

![Figure 1. Morphology of ALK-rearrangement lung adenocarcinoma.](image-url)
rearranged tumors were characterized by a solid or acinar growth pattern and lack of lepidic growth. When compared with common driver mutation tumors, solid or acinar-predominant pattern, cribriform structure, signet-ring cells, hepatoid appearance, prominent extracellular mucus, and any type of mucous cells were all significantly associated with the $\text{ALK}^+$ tumors. This is in agreement with a previous report [13]. When compared with pan-negative tumors, only cribriform structure, prominent extracellular mucus and any type of mucous cells were significantly associated with $\text{ALK}^+$ lung adenocarcinomas. Therefore, our data showed cribriform structure, prominent extracellular mucus and any type of mucous cells pattern are sensitive and/or specific to predict $\text{ALK}$ rearrangement. In most $\text{ALK}$-rearranged tumors, tumor nuclei were relatively monomorphic, except for 2 cases showing focal areas of pleomorphism. These distinct morphologic features of $\text{ALK}$ rearrangement tumors are in

![Figure 2. Two patterns of $\text{ALK}$ gene alteration detected by FISH using Vysis LSI ALK Dual Color breakpoint probe.](doi:10.1371/journal.pone.0069016.g002)

![Figure 3. Immunohistochemical staining with D5F3 and ALK1 detects ALK-rearrangement tumors.](doi:10.1371/journal.pone.0069016.g003)
considered low-throughput, so is not suitable for detecting enrollment in a clinical trial with crizotinib [6]. However, FISH is using the ALK break-apart probe, was the standard test for may not detect all the translocations involving the gene. FISH, case RNA may be substantially degraded. Furthermore, RT-PCR rearrangements while RT-PCR may not be able to detect all translocations involving the gene. FISH, using the ALK break-apart probe, was the standard test for enrollment in a clinical trial with crizotinib [6]. However, FISH is considered low-throughput, so is not suitable for detecting ALK rearrangements in large-scale screening. IHC, however, is a low-cost, relatively easy technique for screening and diagnosis ALK-rearranged tumors in routine surgical pathology practice, although, some ALK antibodies have been reported to lack specificity and sensitivity [4].

We evaluated EML4-ALK fusion variants using RT-PCR and identified that E13; A20 (variant 1), E6a/b; A20 (variant 3a/b), E20; A20 (variant 2) are the most common variants. This frequency of distribution is quite similar to those reported [17]. In our study, 6 RT-PCR-negative cases were FISH-positive, suggesting the present of other unknown variants. In our study, D5F3 antibody showed very little nonspecific or background immunostaining. Its sensitivity and specificity (91% and 98%, respectively) is much higher than that (63.6% and 93%) of ALK1 IHC. There was only 1 false-positive D5F3 case, while 4 ALK1-positive cases were false-positive, and confirmed by FISH. Moreover, D5F3 showed a much higher relative amount of staining and intensity than did the ALK1. ALK1 and D5F3 IHC were positive only in the adenocarcinoma component, but not in the squamous carcinoma component. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 expression, an acinar histology, and young onset. Mod Pathol 22(4): p. 508–15.

In conclusion, we identified 44 ALK-rearranged lung adenocarcinomas, the largest reports in China to date. In our study, ALK-rearranged lung adenocarcinomas were associated with characteristic morphology such as cribriform structure, prominent extracellular mucus, and any type of mucous cell pattern. FISH remains a highly useful and accurate method to identify ALK rearrangements while RT-PCR may not be able to detect all translocations and is technically limited in many pathology departments. IHC, although not as sensitive as FISH, remains the preferred technique for such cases. Also, D5F3 could be the optimal screening tool for detecting ALK rearrangements.

### Acknowledgments

We greatly appreciated Professor Liang Cheng, Department of Pathology and Laboratory Medicine, Indiana University, USA and David Garfield, Promed Cancer Centers, Shanghai, China, for English revision.

### Author Contributions

Conceived and designed the experiments: HQC XZZ. Performed the experiments: YL YJP. Obtained the data: YL YJP. Contributed reagents/materials/analysis tools: YL YJP. Wrote the paper: YL YJP. Reviewed and revised the manuscript: HQC XZZ.

### References

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (7153): 561–566.
2. Kim H, Yoo SB, Cheo JY, Paik JH, Xu X, et al. (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6(8): 1359–1366.
3. Paik JH, Cho G, Kim H, Cheo JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6(3): 466–472.
4. Martelli MP, Sozzi G, Hernandez L, Petrirosso V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174(2): 661–670.
5. Inamura K, Takeschi K, Togashi Y, Hatano S, Ninnomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22(4): p. 508–15.
6. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11): 1004–1012.

### Table 3. Comparison between RT-PCR and IHC.

| IHC   | RT-PCR |
|-------|--------|
|       | Positive | Negative |
| D5F3  |         |          |
| Positive | 36      | 5        |
| Negative | 2       | 118      |
| ALK1  |         |          |
| Positive | 26      | 2        |
| Negative | 12      | 121      |

Abbreviation: RT-PCR: Reverse Transcription-Polymerase Chain Reaction; IHC: immunohistochemistry.

doi:10.1371/journal.pone.0069016.t003

### Table 4. Comparison between FISH and IHC.

| IHC   | FISH |
|-------|------|
|       | Positive | Negative |
| D5F3  |         |          |
| Positive | 40      | 1        |
| Negative | 4       | 116      |
| ALK1  |         |          |
| Positive | 28      | 4        |
| Negative | 16      | 113      |

Abbreviation: FISH: Fluorescence In Situ Hybridization; IHC: immunohistochemistry.

doi:10.1371/journal.pone.0069016.t004
7. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16(3): 1561–1571.

8. Sun Y, Ren Y, Fang Z, Li G, Fang R, et al. (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28(30): 4616–4620.

9. Wang R, Pan Y, Li C, Hu H, Zhang Y, et al. (2012) The Use of Quantitative Real-time Reverse-Transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK Rearrangements in Lung Cancers. Clin Cancer Res 18(17): 4725–4732.

10. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2): 244–283.

11. Sica G, Yoshizawa A, Sama CS, Azoli CG, Downey RJ, et al. (2010) A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 34(8): 1153–1162.

12. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26): 4247–4253.

13. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, et al. (2012) Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 25(11): 1462–1472.

14. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14(28): 8618–8624.

15. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15(16): 5216–5223.

16. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35(8): 1226–1234.

17. Sasaki T, Rodig SJ, Chirieac LR, Janne PA (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 46(10): 1773–1780.